NCT04446416 2026-04-09
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
NaviFUS Corporation
Phase NA Completed
NaviFUS Corporation
M.D. Anderson Cancer Center
University of Southern California
University of Miami
Memorial Sloan Kettering Cancer Center